STATE-OF-THE-ART REVIEW

Role of Contact Force Sensing in Catheter Ablation of Cardiac Arrhythmias

Evolution or History Repeating Itself?

Nilshan Ariyarathna, BSc(MED)/MBBS, MMED (CLIN EPI),^a Saurabh Kumar, BSc(MED)/MBBS, PHD,^b Stuart P. Thomas, BMED, PHD,^b William G. Stevenson, MD,^c Gregory F. Michaud, MD^c

JACC: CLINICAL ELECTROPHYSIOLOGY CME/MOC

This article has been selected as the month's *JACC: Clinical Electrophysiology* CME/MOC activity, available online at www.jacc-electrophysiology.org by selecting the *JACC* Journals CME/MOC tab.

Accreditation and Designation Statement

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACCF designates this Journal-based CME/MOC activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation and Receipt of CME/MOC Certificate

To obtain credit for JACC: Clinical Electrophysiology CME/MOC, you must:

- 1. Be an ACC member or JACC: Clinical Electrophysiology subscriber.
- Carefully read the CME/MOC-designated article available online and in this issue of the journal.
- 3. Answer the post-test questions. At least 2 out of the 3 questions provided must be answered correctly to obtain CME/MOC credit.
- 4. Complete a brief evaluation.
- Claim your CME/MOC credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

CME/MOC Objective for This Article: Upon completion of this activity, the learner should be able to: 1) identify and compare the strengths

and limitations of using surrogate markers of tissue contact; 2) describe the impact that contact force has on lesion size, ablation safety and efficacy; and 3) discuss the impact of contact force quality metrics on ablation efficacy.

CME/MOC Editor Disclosure: CME/MOC Editor Smit Vasaiwala, MD, has nothing to declare.

Author Disclosures: Dr. Kumar is a recipient of the Neil Hamilton Fairley Overseas Research scholarship, cofunded by the National Health and Medical Research Council and the National Heart Foundation of Australia, and the Bushell Travelling Fellowship, funded by the Royal Australasian College of Physicians. Dr. Stevenson is co-holder of a patent for needle ablation that is consigned to Brigham and Women's Hospital; his spouse receives research support from St. Jude Medical; and has received speaker honoraria from Boston Scientific and Biosense Webster. Dr. Michaud has received consulting fees/honoraria from Boston Scientific, Biotronik, Medtronic, and Abbott/St. Jude Medical; and has received research funding from Boston Scientific and Biosense Webster. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Medium of Participation: Print (article only); online (article and quiz).

CME/MOC Term of Approval

Issue Date: June 2018 Expiration Date: May 31, 2019

From the ^aCardiology Department, The Canberra Hospital, Canberra, Australian Capital Territory, Australia; ^bDepartment of Cardiology, Westmead Hospital, Westmead Applied Research Centre, University of Sydney, New South Wales, Australia; and the ^cArrhythmia and Electrophysiology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Dr. Kumar is a recipient of the Neil Hamilton Fairley Overseas Research scholarship, cofunded by the National Health and Medical Research Council and the National Heart Foundation of Australia, and the Bushell Travelling Fellowship, funded by the Royal Australasian College of Physicians. Dr. Stevenson is co-holder of a patent for needle ablation that is consigned to Brigham and Women's Hospital; his spouse receives research support from St. Jude Medical; and has received speaker honoraria from Boston Scientific and Biosense Webster. Dr. Michaud has received consulting fees/honoraria from Boston Scientific, and Abbott/St. Jude Medical; and has received research funding from Boston Scientific and Biosense Webster. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Ariyarathna and Kumar contributed equally to this work and are joint first authors.

Role of Contact Force Sensing in Catheter Ablation of Cardiac Arrhythmias

Evolution or History Repeating Itself?

Nilshan Ariyarathna, BSc(MED)/MBBS, MMED (CLIN EPI),^a Saurabh Kumar, BSc(MED)/MBBS, PHD,^b Stuart P. Thomas, BMED, PHD,^b William G. Stevenson, MD,^c Gregory F. Michaud, MD^c

ABSTRACT

Adequate catheter-tissue contact facilitates efficient heat energy transfer to target tissue. Tissue contact is thus critical to achieving lesion transmurality and success of radiofrequency (RF) ablation procedures, a fact recognized more than 2 decades ago. The availability of real-time contact force (CF)-sensing catheters has reinvigorated the field of ablation biophysics and optimized lesion formation. The ability to measure and display CF came with the promise of dramatic improvement in safety and efficacy; however, CF quality was noted to have just as important an influence on lesion formation as absolute CF quantity. Multiple other factors have emerged as key elements influencing effective lesion formation, including catheter stability, lesion contiguity and continuity, lesion density, contact homogeneity across a line of ablation, spatiotemporal dynamics of contact governed by cardiac and respiratory motion, contact directionality, and anatomic wall thickness, in addition to traditional ablation indices of power and RF duration. There is greater appreciation of surrogate markers as a guide to lesion formation, such as impedance fall, loss of pace capture, and change in unipolar electrogram morphology. In contrast, other surrogates such as tactile feedback, catheter motion, and electrogram amplitude are notably poor predictors of actual contact and lesion formation. This review aims to contextualize the role of CF sensing in lesion formation with respect of the fundamental principles of biophysics of RF ablation and summarize the state-of-the-art evidence behind the role of CF in optimizing lesion formation. (J Am Coll Cardiol EP 2018;4:707-23) © 2018 by the American College of Cardiology Foundation.

fforts at refining ablation technology are driven by the modest success rates of catheter ablation procedures for atrial and ventricular arrhythmias. Pulmonary vein (PV) isolation (PVI) is the paradigm that illustrates the deficiencies of contemporary radiofrequency (RF) ablation technology. Although electrical disconnection of the PV from the left atrium (LA) can be achieved almost universally by the end of the procedure, long-term efficacy remains modest, with single- and multiple-procedure success rates of 54% and 79% for paroxysmal atrial fibrillation (AF) over long-term follow-up (\geq 3 years) (1). Resumption of PV-LA conduction is the chief mechanism of AF recurrence after catheter ablation of paroxysmal AF (2-4). Achieving durable PVI is thus the ultimate goal in enhancing procedural efficacy. Even in an arrhythmia with a well-defined mechanism, such as typical cavotricuspid isthmus (CTI)-dependent atrial flutter, recurrent

conduction can be seen in up to 23% of patients at late restudy (5), with single-procedure success of 92%, which suggests incomplete lesion efficacy with contemporary technologies (6). When myocardial thickness increases and the substrate for arrhythmia becomes more complex, such as with ventricular tachycardia, ablation efficacy is even lower, with ventricular tachycardia-free survival achievable in only 50% to 88% with ischemic cardiomyopathy and 41% to 53% in nonischemic cardiomyopathy, often with multiple procedures (7).

Current research on enhancing the efficacy of RF ablation has focused on understanding the influence of catheter-tissue contact force (CF) on lesion formation. The contribution of CF to the creation of effective lesions and the ultimate success of a catheter ablation procedure were recognized more than 2 decades ago (8). The inability to measure imparted CF meant that for decades, operators used indirect

Manuscript received October 23, 2017; revised manuscript received March 12, 2018, accepted March 22, 2018.

All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC: Clinical Electrophysiology* author instructions page.

Download English Version:

https://daneshyari.com/en/article/8664390

Download Persian Version:

https://daneshyari.com/article/8664390

Daneshyari.com